Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aimed to assess the outcome and prognostic factors in a multicenter population of women treated for primary ULMS. We retrospectively collected data of 110 women treated in 19 institutions of the Rare Cancer Network (RCN). Inclusion criteria consisted of a pathology report confirming the diagnosis of ULMS, aged 18-80 years, complete International Federation of Gynecology and Obstetrics (FIGO) stage information, complete information on treatment, and a minimum follow-up of 6 months. Local control (LC) and locoregional control (LRC), overall survival (OS) and disease-free survival (DFS) rates were computed using the Kaplan-Meier method. Univariate a...
BACKGROUND: Between 30% and 50% of women who have high-grade uterine leiomyosarcoma (uLMS) limited t...
textabstractAlthough leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs)...
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...
Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prog...
Objectives: It was the aim of this study to evaluate clinicopathological characteristics and prognos...
Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and progn...
Objective About 50-60% of patients with stage I-II uterine leiomyosarcoma (ULMS), primarily treated ...
Uterine leiomyosarcomas (LMSs) are rare cancers representing less than 1% of all uterine malignancie...
Background and Methods: Uterine leiomyosarcomas (uLMS) are rare malignant tumors, often incidentally...
Objective To determine the survival data for the various tumour types of uterine sarcoma and determi...
Background/aim: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomy...
Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5...
Background: Uterine sarcoma is an uncommon aggressive malignancy. Optimal management and prognostic ...
BACKGROUND: Between 30% and 50% of women who have high-grade uterine leiomyosarcoma (uLMS) limited t...
textabstractAlthough leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs)...
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...
Primary uterine leiomyosarcomas (ULMS) are rare, and the optimal treatment is controversial. We aime...
Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and prog...
Objectives: It was the aim of this study to evaluate clinicopathological characteristics and prognos...
Objective: To evaluate the clinicopathologic characteristics, treatment methods, survival, and progn...
Objective About 50-60% of patients with stage I-II uterine leiomyosarcoma (ULMS), primarily treated ...
Uterine leiomyosarcomas (LMSs) are rare cancers representing less than 1% of all uterine malignancie...
Background and Methods: Uterine leiomyosarcomas (uLMS) are rare malignant tumors, often incidentally...
Objective To determine the survival data for the various tumour types of uterine sarcoma and determi...
Background/aim: This study aimed to evaluate the role of adjuvant therapy for stage I uterine leiomy...
Uterine leiomyosarcomas (Ut-LMSs) are aggressive tumors with an overall poor prognosis (15% to 25% 5...
Background: Uterine sarcoma is an uncommon aggressive malignancy. Optimal management and prognostic ...
BACKGROUND: Between 30% and 50% of women who have high-grade uterine leiomyosarcoma (uLMS) limited t...
textabstractAlthough leiomyosarcomas (LMSs) form the largest subgroup of soft tissue sarcomas (STSs)...
Ovarian sarcomas account for 1% of all ovarian malignancies and amongst these, primary ovarian leiom...